Recent Advances in Cardiac Tissue Engineering for the Management of Myocardium Infarction
Vineeta Sharma,
Sanat Kumar Dash,
Kavitha Govarthanan,
Rekha Gahtori,
Nidhi Negi,
Mahmood Barani,
Richa Tomar,
Sudip Chakraborty,
Santosh Mathapati,
Dillip Kumar Bishi,
Poonam Negi,
Kamal Dua,
Sachin Kumar Singh,
Rohit Gundamaraju,
Abhijit Dey,
Janne Ruokolainen,
Vijay Kumar Thakur,
Kavindra Kumar Kesari,
Niraj Kumar Jha,
Piyush Kumar Gupta,
Shreesh Ojha
Affiliations
Vineeta Sharma
Stem Cell and Molecular Biology Laboratory, Department of Biotechnology, Indian Institute of Technology Madras, Bhupat and Jyoti Mehta School of Biosciences, Chennai 600036, India
Sanat Kumar Dash
Heat Transfer and Thermal Power Laboratory, Department of Mechanical Engineering, Indian Institute of Technology Madras, Chennai 600036, India
Kavitha Govarthanan
Stem Cell and Molecular Biology Laboratory, Department of Biotechnology, Indian Institute of Technology Madras, Bhupat and Jyoti Mehta School of Biosciences, Chennai 600036, India
Rekha Gahtori
Department of Biotechnology, Sir J. C. Bose Technical Campus, Kumaun University, Nainital 263136, India
Nidhi Negi
Department of Chemistry, DSB Campus, Kumaun University, Nainital 263001, India
Mahmood Barani
Medical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman 7616913555, Iran
Richa Tomar
Department of Chemistry and Biochemistry, School of Basic Sciences and Research, Sharda University, Knowledge Park III, Greater Noida 201310, India
Sudip Chakraborty
School of Chemistry, University of New South Wales, Anzac Parade, Kensington, NSW 2033, Australia
Santosh Mathapati
Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurugram Expressway, Faridabad 121001, India
Dillip Kumar Bishi
Department of Biotechnology, Rama Devi Women’s University, Bhubaneswar 751022, India
Poonam Negi
School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173212, India
Kamal Dua
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, Sydney, NSW 2007, Australia
Sachin Kumar Singh
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144001, India
Rohit Gundamaraju
ER Stress and Mucosal Immunology Laboratory, School of Health Sciences, University of Tasmania, Launceston, TAS 7248, Australia
Abhijit Dey
Department of Life Sciences, Presidency University, College Street, Kolkata 700073, India
Janne Ruokolainen
Department of Applied Physics, School of Science, Aalto University, 00076 Espoo, Finland
Vijay Kumar Thakur
Biorefining and Advanced Materials Research Centre, Scotland’s Rural College (SRUC), Kings Buildings, Edinburgh EH9 3JG, UK
Kavindra Kumar Kesari
Department of Applied Physics, School of Science, Aalto University, 00076 Espoo, Finland
Niraj Kumar Jha
Department of Biotechnology, School of Engineering and Technology, Sharda University, Knowledge Park III, Greater Noida 201310, India
Piyush Kumar Gupta
Department of Life Sciences, School of Basic Sciences and Research, Sharda University, Knowledge Park III, Greater Noida 201310, India
Shreesh Ojha
Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 17666, United Arab Emirates
Myocardium Infarction (MI) is one of the foremost cardiovascular diseases (CVDs) causing death worldwide, and its case numbers are expected to continuously increase in the coming years. Pharmacological interventions have not been at the forefront in ameliorating MI-related morbidity and mortality. Stem cell-based tissue engineering approaches have been extensively explored for their regenerative potential in the infarcted myocardium. Recent studies on microfluidic devices employing stem cells under laboratory set-up have revealed meticulous events pertaining to the pathophysiology of MI occurring at the infarcted site. This discovery also underpins the appropriate conditions in the niche for differentiating stem cells into mature cardiomyocyte-like cells and leads to engineering of the scaffold via mimicking of native cardiac physiological conditions. However, the mode of stem cell-loaded engineered scaffolds delivered to the site of infarction is still a challenging mission, and yet to be translated to the clinical setting. In this review, we have elucidated the various strategies developed using a hydrogel-based system both as encapsulated stem cells and as biocompatible patches loaded with cells and applied at the site of infarction.
